首页> 外文期刊>JAMA: the Journal of the American Medical Association >Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation.
【24h】

Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation.

机译:心脏特异的肌钙蛋白I水平以及心脏移植后冠状动脉疾病和移植失败的风险。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Previous studies have yielded conflicting data regarding whether a relationship exists between elevated cardiac troponin levels and acute allograft rejection in patients who have received heart transplants. OBJECTIVE: To determine whether cardiac troponin I levels after heart transplantation were associated with a procoagulant microvasculature and long-term allograft outcome. DESIGN: Prospective cohort study with a mean (SE) follow-up of 45.1 (2.5) months. Serum troponin I levels were measured 9.9 (0.2) times per patient during the first 12 months after heart transplantation. SETTING: Heart transplant center in the United States. PATIENTS: A total of 110 consecutive patients who received a heart transplant between 1989 and 1997 and survived at least 1 year after transplantation. MAIN OUTCOME MEASURES: Histological and immunohistochemical biopsy findings, development of coronary artery disease (CAD), and graft failure in patients with vs without elevated serum cardiac troponin I levels. RESULTS: All recipients had elevated troponin I levels during the first month after transplantation. Troponin I levels remained persistently elevated during the first 12 months in 56 patients (51%) and became undetectable in 54 patients (49%). Persistently elevated troponin I levels were associated with increasing fibrin deposits in microvasculature and cardiomyocytes (P<.001). Patients with persistently elevated levels of troponin I had significantly increased risk for subsequent development of CAD (odds ratio [OR], 4. 3; 95% confidence interval [CI], 1.8-10.1; P<.001) and graft failure (OR, 3.4; 95% CI, 1.2-9.7; P =.02), and also developed more severe CAD (OR, 4.2; 95% CI, 1.9-9.3; P<.001) and showed more disease progression (OR, 3.7; 95% CI, 1.3-10.4; P =.009). CONCLUSION: In this study, elevated cardiac troponin I levels, which are considered to be a noninvasive surrogate marker of a procoagulant microvasculature, identified a subgroup of patients with high risk for developing CAD and graft failure after cardiac transplantation. JAMA. 2000;284:457-464
机译:背景:关于接受心脏移植的患者中心脏肌钙蛋白水平升高与急性同种异体排斥反应之间是否存在关系,先前的研究得出了相互矛盾的数据。目的:确定心脏移植后心脏肌钙蛋白I水平是否与促凝微血管系统和长期同种异体移植结果有关。设计:前瞻性队列研究,平均(SE)随访45.1(2.5)个月。在心脏移植后的前12个月中,每位患者的血清肌钙蛋白I水平为9.9(0.2)倍。地点:美国心脏移植中心。患者:1989年至1997年期间,共有110位连续患者接受了心脏移植,并在移植后至少存活了1年。主要观察指标:有或没有血清心肌肌钙蛋白I水平升高的患者的组织学和免疫组织化学活检结果,冠状动脉疾病(CAD)的发展以及移植失败。结果:所有接受者在移植后的第一个月内肌钙蛋白I水平升高。在最初的12个月中,有56例患者(51%)的肌钙蛋白I水平持续升高,而有54例患者(49%)无法检测到。持续升高的肌钙蛋白I水平与微血管和心肌细胞中纤维蛋白沉积的增加有关(P <.001)。肌钙蛋白I水平持续升高的患者随后发生CAD的风险显着增加(几率[OR]为4. 3; 95%置信区间[CI]为1.8-10.1; P <.001)和移植失败(OR ,3.4; 95%CI,1.2-9.7; P = .02),并且发展为更严重的CAD(OR,4.2; 95%CI,1.9-9.3; P <.001),并显示出更多的疾病进展(OR,3.7) ; 95%CI,1.3-10.4; P = .009)。结论:在这项研究中,升高的心肌肌钙蛋白I水平被认为是促凝性微脉管系统的一种非侵入性替代指标,确定了心脏移植后发生CAD和移植失败的高风险患者亚组。贾玛2000; 284:457-464

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号